Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial | Farina et al.
The present study provides the first clinical evidence suggesting that pharmacological inhibition of oxLDL with an anti-oxLDL antibody may reduce coronary inflammation. Residual inflammation remains an important risk factor for recurrent events in cardiovascular patients receiving guideline preventive therapy. It is an interesting possibility that the combination of FAI screening and orticumab treatment could be used to identify and reduce risk in this population.
Christopher J Farina, Michael H Davidson, Prediman K Shah, Charles Stark, Wenqi Lu, Cheerag Shirodaria, Timothy Wright, Charalambos A Antoniades, Jan Nilsson, Nehal N Mehta, Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial, Cardiovascular Research, 2024;, cvae057, https://doi.org/10.1093/cvr/cvae057
